You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

478 Results
Document
Sep 2023
Document
Sep 2023
Statistical Reports
Jan 2024
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Curative, Palliative
Funding:
New Drug Funding Program
    Dostarlimab - Primary Advanced or Recurrent MSI-H or dMMR Endometrial Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
dostarlimab,
PACLitaxel,
CARBOplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2025
Document
Feb 2024
Document
Feb 2024
Document
Feb 2024
Document
Feb 2024
Document
May 2024
Document
May 2024
Document
May 2024

Pages